Johnson & Johnson, the popular company, has completed its acquisition of Halda Therapeutics OpCo, Inc., a known clinical-level biotechnology company. Along with this acquisition, Johnson & Johnson will now have the authority to use Halda’s exclusive Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform. This platform will help to establish targeted oral therapies for various types of solid tumors involving prostate cancer, worth $3.05 billion in cash.
The Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson, Jennifer Taubert, said, “This unforgettable smart milestone represents our dedication to reintroducing cancer treatment with impeccable, transformative medicines and science. We are thrilled to welcome the remarkable Halda team to our company space. Furthermore, we are looking forward to developing excellence together to succeed in the joint goal of discarding cancer.”
Johnson & Johnson will integrate Halda’s HLD-0915, a clinical-level therapy for prostate cancer, which is Halda’s robust existing innovation for years in this disease space. The HLD-0915 is a once-a-day oral therapy which is operative using a novel RIPTAC™ platform with an accurate cancer cell-killing idea that can fight mechanisms of obstruction to treatment.
Moreover, the Company integrates numerous earlier candidates for lung, breast and various other tumor types based on the robust RIPTAC™ technology to its popular oncology portfolio. This technology may also allow the discovery of transitional targeted therapies apart from oncology.
MD., PhD, Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson, John C. Reed, said, “Our company is also looking for new ways to satisfy patient needs and serve innovative therapies. After the confirmation and completion of this acquisition, we will concentrate on modernising the potential value of this convincing pipeline of novel product candidates and hold on to the comprehensive RIPTAC™ platform to explore more molecules in oncology and other streams as well.”
This acquisition will be a part of a business merger as the deal includes transactions that will be closed in 2025. Following this the Johnson & Johnson hopes for the dilution in Q4 2025 and 2026 profit. Overall, the dilution figure for the Adjusted Earnings Per Share (EPS) of an estimated $0.20 is predicted to be divided equally between this running year 2025 and 2026.
The split will be based on the recent estimates for the exceptional charge regarding Halda’s employee equity awards, integration and financing costs. Johnson & Johnson will deliver a voice of guidance for 2026 during the fourth quarter earnings call scheduled on Wednesday, 21st January 2026.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
